Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.11.2016 | original article | Ausgabe 21-22/2016

Wiener klinische Wochenschrift 21-22/2016

The evaluation in terms of sarcopenia of patients with fibromyalgia syndrome

Wiener klinische Wochenschrift > Ausgabe 21-22/2016
MD Dr. Irfan Koca, Esen Savas, Zeynel Abidin Ozturk, Ahmet Boyaci, Ahmet Tutoglu, Samet Alkan, Hamit Yildiz, Gezmiş Kimyon



Fibromyalgia syndrome (FMS) is an extra-articular rheumatic illness, characterized by widespread body pain and decreased muscle function. Generalized loss of muscle mass and strength is named as sarcopenia. The objective of this study was to evaluate patients with FMS regarding sarcopenia.


This was a cross sectional, case-controlled, single-blinded, and single-centered study. The FMS patients were assessed by Fibromyalgia Impact Questionnaire (FIQ), visual analog scale (VAS), Beck Depression Index (BDI), and Pittsburg Sleep Quality Scale (PSQI). All the participants were evaluated for sarcopenia by bioimpedance analysis (BIA), anthropometric measurements, handgrip strength, and the parameters of walking speed.


In this study, 82 patients with FMS and 38 healthy control female subjects were included. VAS, BDI, and PSQI scores were statistically higher in the FMS group than the control group (p < 0.001). Handgrip strength (HS) and walking speed (WS) scores in the group with FMS were statistically lower than the control group (p = 0.023, p < 0.001 respectively). VAS score of FMS patients was significantly correlated with BIA, body mass index, waist circumference, HS, and WS scores (r = 0.284, p = 0.012; r = 0.228, p = 0.045; r = 0.249, p = 0.028; r = − 0.361, p = 0.001; and r = − 0.230, p = 0.043 respectively). Also FIQ in patients was significantly correlated with BIA, waist circumference, HS, WS, and body mass index (r = 0.267, p = 0.018; r = 0.291, p = 0.010; r = − 0.319, p = 0.004; r = − 0.360, p = 0.001; and r  = 0.304, p = 0.007 respectively).


Evaluation of female patients with primary FMS by the sarcopenia parameters could contribute a more objective evaluation during the patients’ follow-up.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 21-22/2016

Wiener klinische Wochenschrift 21-22/2016 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien